These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10404926)

  • 41. Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?
    Hankey GJ
    Stroke; 2002 Jun; 33(6):1723-6. PubMed ID: 12053018
    [No Abstract]   [Full Text] [Related]  

  • 42. Additional risk factors in atrial fibrillation patients not receiving warfarin.
    Wensley S; Keir S; Caine S; Mac Mahon M
    Age Ageing; 1999 Jul; 28(4):355-7. PubMed ID: 10459787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.
    Lancet; 1998 Jan; 351(9098):233-41. PubMed ID: 9457092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
    Lancet; 1994 Mar; 343(8899):687-91. PubMed ID: 7907677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design.
    Pullicino P; Thompson JL; Barton B; Levin B; Graham S; Freudenberger RS;
    J Card Fail; 2006 Feb; 12(1):39-46. PubMed ID: 16500579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
    Homma S; Thompson JL; Qian M; Ye S; Di Tullio MR; Lip GY; Mann DL; Sacco RL; Levin B; Pullicino PM; Freudenberger RS; Teerlink JR; Graham S; Mohr JP; Labovitz AJ; Buchsbaum R; Estol CJ; Lok DJ; Ponikowski P; Anker SD;
    Circ Heart Fail; 2015 May; 8(3):504-9. PubMed ID: 25850425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy?
    Bellelli G; Barbisoni P; Gusmeri A; Sabatini T; Rozzini R; Trabucchi M
    J Am Geriatr Soc; 1999 Aug; 47(8):1034-5. PubMed ID: 10443869
    [No Abstract]   [Full Text] [Related]  

  • 49. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study.
    Petty GW; Brown RD; Whisnant JP; Sicks JD; O'Fallon WM; Wiebers DO
    Ann Intern Med; 1999 Jan; 130(1):14-22. PubMed ID: 9890845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombotic therapy in atrial fibrillation.
    Turpie AG; Connolly SJ
    Can Fam Physician; 1996 Jul; 42():1341-5. PubMed ID: 8754703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
    Gage BF; Cardinalli AB; Albers GW; Owens DK
    JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.
    Kutner M; Nixon G; Silverstone F
    Arch Intern Med; 1991 Oct; 151(10):1950-3. PubMed ID: 1929682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.
    Bajorek B; Magin PJ; Hilmer S; Krass I
    J Clin Pharm Ther; 2016 Aug; 41(4):432-40. PubMed ID: 27338004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does the combination of warfarin and aspirin have a place in secondary stroke prevention? No.
    Fisher M
    Stroke; 2009 May; 40(5):1944-5. PubMed ID: 19299634
    [No Abstract]   [Full Text] [Related]  

  • 56. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
    Testa L; Zoccai GB; Porto I; Trotta G; Agostoni P; Andreotti F; Crea F
    Am J Cardiol; 2007 Jun; 99(12):1637-42. PubMed ID: 17560866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
    Schwann TA; Habib RH; Suri RM; Brennan JM; He X; Thourani VH; Engoren M; Ailawadi G; Englum BR; Bonnell MR; Gammie JS
    Chest; 2016 Sep; 150(3):597-605. PubMed ID: 27132702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation.
    Kan BD; Katz DA
    JAMA; 1996 Mar; 275(12):909; author reply 910. PubMed ID: 8598612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.